Sandoz has agreed to wait until March 2030 to launch a generic version of Adamas Pharmaceuticals’ Gocovri (adamantadine) extended-release capsules in the US. However, Novartis’ generics division may be able to bring that entry date forward if volume sales of the dyskinesia treatment decline versus current levels.
Sandoz Will Wait A Decade On Amantadine
Patent-Litigation Settlement Permits 2030 Launch
Sandoz will be able to launch a generic of Adamas’ amantadine-based Gocovri brand in the US from March 2030. But a patent-litigation settlement permits an earlier entry if sales of the dyskinesia brand decline.
